Banque Transatlantique SA Makes New $473,000 Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Banque Transatlantique SA invested approximately $473,000 in Teva Pharmaceutical Industries, acquiring 33,324 shares during the first quarter as per its SEC filing.
• Teva's recent quarterly earnings indicated an EPS of $0.66, surpassing estimates by $0.02, with a revenue of $4.18 billion.
• Institutional investors collectively own 54.05% of Teva Pharmaceutical's stock, demonstrating strong interest from the financial sector.

Banque Transatlantique SA bought a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund bought 33,324 shares of the company's stock, valued at approximately $473,000.

Other large investors have also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $39,000. New Age Alpha Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $43,000. Compagnie Lombard Odier SCmA purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $54,000. Banque Cantonale Vaudoise purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $74,000. Finally, Brooklyn Investment Group boosted its stake in shares of Teva Pharmaceutical Industries by 403.4% during the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock worth $77,000 after purchasing an additional 4,014 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Up 2.5%

Shares of NYSE:TEVA traded up $0.46 during trading hours on Friday, hitting $18.94. The company's stock had a trading volume of 7,802,703 shares, compared to its average volume of 9,725,214. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The company has a market capitalization of $21.72 billion, a price-to-earnings ratio of -118.35, a P/E/G ratio of 1.12 and a beta of 0.72. The firm's fifty day moving average price is $17.04 and its 200 day moving average price is $16.40.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. During the same quarter in the previous year, the business posted $0.61 EPS. The company's quarterly revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on TEVA shares. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and an average target price of $24.71.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.